Search clinical trials for: Consolidative Durvalumab

Total 837 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Systemic Therapy With or Without Local Consolidative Therapy in Treating Patients With Oligometastatic Solid Tumor

Oligometastatic Malignant Solid Neoplasm

United States
University of Nebraska
AstraZeneca

Recruiting

Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab

Lung Cancer | Carcinoma, Non-Small Cell Lung

United States
University of Texas Southwestern Medical Center
AstraZeneca

Active, not recruiting

Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | Lung Cancer Stage III

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Advanced Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma | ALK Gene Rearrangement

United States
Tata Memorial Hospital

Recruiting

Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC (TARGET-01)

Non-small Cell Lung Cancer | Oligometastatic Disease | Driver Mutation

India
Jiangxi Provincial Cancer Hospital

Recruiting

Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma (NPC-CR01)

Oligometastatic Disease

China
Shandong Cancer Hospital and Institute

Unknown

Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC (CONSIST)

Carcinoma, Non-Small Cell Lung

China
Instituto Politécnico de Castelo Branco

Completed

Chronic Effects of Exercise on Motor Memory Consolidation in Elderly People

Elderly
Affiliated Cancer Hospital & Institute of Guangzhou...

Not yet recruiting

Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases

Lung Cancer | Radiotherapy | Extensive-stage Small-cell Lung Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC

Head and Neck Squamous Cell Carcinomas

China
Wuhan Union Hospital, China

Not yet recruiting

Consolidative Radiotherapy Plus Maintenance Chemotherapy for Metastatic Colorectal Cancer (MCRC-LC1)

Metastatic Colorectal Cancer | Radiotherapy

China
Guangdong Association of Clinical Trials

Recruiting

Local Therapy in Advanced NSCLC With Non-progressive Disease (PD) After First Line Therapy (LOCAL)

Lung Neoplasms

China
Rachel Sanborn
AstraZeneca; Providence Cancer Center, Earle A. Chiles Research Institute

Active, not recruiting

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

Lung Cancer | Non-small Cell Carcinoma

United States
French Innovative Leukemia Organisation

Terminated

Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma

B-cell Lymphoma

France
AstraZeneca
Kappa Santé

Recruiting

A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer. (ARSENAL)

Small Cell Lung Carcinoma

France
Yonsei University

Recruiting

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

Potentially Resectable Stage II/IIIa NSCLC

Korea, Republic of
Academic Thoracic Oncology Medical Investigators...
AstraZeneca

Completed

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Non-Small Cell Lung Cancer NSCLC

United States
Yonsei University

Completed

A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma

Sarcoma

Korea, Republic of
NSABP Foundation Inc

Completed

Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer

Rectal Cancer

United States
MedImmune LLC

Completed

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST)

Stage III Non-small Cell Lung Cancer | Unresectable

United States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
Fox Chase Cancer Center
Varian Medical Systems

Withdrawn

Local Consolidative Therapy in Colorectal Cancer

Colorectal Cancer Metastatic

United States
Hark Kyun Kim

Recruiting

Vactosertib and Durvalumab in Gastric Cancer

Stomach Neoplasm

Korea, Republic of
Oslo University Hospital
AstraZeneca

Active, not recruiting

Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study (DART)

Cancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage III

Norway, Finland, Lithuania, Estonia
MedImmune LLC

Completed

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

Advanced Solid Tumors

United States, France, Spain, Switzerland
AstraZeneca

Completed

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

Advanced Malignancy

China
Yonsei University

Not yet recruiting

Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)

Non Small Cell Lung Cancer

Korea, Republic of
Biocity Biopharmaceutics Co., Ltd.

Not yet recruiting

BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Memorial Sloan Kettering Cancer Center
AstraZeneca; MedImmune LLC

Active, not recruiting

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

Thyroid Cancer

United States
Canadian Cancer Trials Group
AstraZeneca

Active, not recruiting

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Solid Malignancies

Canada
Assistance Publique - Hôpitaux de Paris
AstraZeneca

Recruiting

Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation (DUMELEP)

BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA

France
Tata Memorial Hospital

Recruiting

Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC (TARGET-02)

Oligometastatic Disease | Metastatic Non Small Cell Lung Cancer

India
Grupo Espanol Multidisciplinario del Cancer Digestivo
AstraZeneca; Vall d'Hebron Institute of Oncology (VHIO)

Recruiting

Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer (DUREC)

Rectal Cancer

Spain
Institut Cancerologie de l'Ouest
AstraZeneca

Active, not recruiting

Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736) (POSTCARD)

Bone Metastases | Prostate Cancer Patients | Node; Prostate

France
ETOP IBCSG Partners Foundation
AstraZeneca AG Switzerland

Not yet recruiting

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. (ADOPT-lung)

Non Small Cell Lung Cancer
AstraZeneca

Active, not recruiting

A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC) (TopDouble)

Biliary Tract Cancers

China
Institut Claudius Regaud

Active, not recruiting

A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation (SILK BM)

NSCLC

France
AstraZeneca

Completed

Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
University Hospital, Grenoble
French Innovative Leukemia Organisation

Completed

Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma (LTP)

Peripheral T Cell Lymphoma

France
Instituto Politécnico de Castelo Branco

Completed

Physical Activity and Motor Memory in Pedal Dexterity

Elderly
University Medical Center Groningen
Cambridge University Hospitals NHS Foundation Trust

Recruiting

Quantitative Fluorescence Endoscopy Using Durvalumab-680LT in Esophageal Cancer (OPTIC)

Esophageal Cancer

Netherlands
Asan Medical Center
Samsung Medical Center

Active, not recruiting

Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer (DEBATE)

Cholangiocarcinoma | Biliary Tract Neoplasms | Gallbladder Cancer

Korea, Republic of
John L. Villano, MD, PhD

Active, not recruiting

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Tumor, Solid

United States
Swiss Group for Clinical Cancer Research

Active, not recruiting

Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. (SAKK 06/17)

Urothelial Cancer

Germany, Switzerland
Yonsei University

Completed

Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing

Metastatic Breast Cancer

Korea, Republic of
Samsung Medical Center

Active, not recruiting

Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC

Head and Neck Squamous Cell Carcinoma

Korea, Republic of
AstraZeneca

Completed

Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)

Small Cell Lung Carcinoma Extensive Disease

China
M.D. Anderson Cancer Center

Not yet recruiting

A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)

OligoProgressive Metastatic Disease

United States
Northern Italy Leukemia Group
Associazione Italiana per la Ricerca sul Cancro

Completed

Treatment of Adult ALL With an MRD-directed Programme.

Acute Lymphoblastic Leukemia

Italy
Memorial Sloan Kettering Cancer Center
AstraZeneca

Completed

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Adenocarcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder | Metastatic Bladder Cancer | Non-Transitional Cell Carcinoma of the Urothelial Tract | Small Cell of the Bladder

United States
AstraZeneca

Completed

An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG)

Advanced Solid Malignancies

United States, Germany, Italy, United Kingdom, Canada, France, Korea, Republic of, Netherlands

Search clinical trials for: Consolidative Durvalumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations